Publications and Presentations
AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors.
Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysis
AXA-042 – a novel systemic TLR2/6 agonist for anti-tumor therapy